Managing Risks In The Development And Manufacture Of Potent Pharmaceuticals Products
Source: Pharmaceutics International

Due to perceived and real risks, certain classes of pharmaceutical products have historically been manufactured in dedicated or segregated, self-contained facilities, in order to mitigate cross-contamination concerns. Recent market reports suggest there’s an increasing number of niche and orphan drugs in development, rendering dedicated production facilities less practical. Given the variety of products currently in development, including potent drugs, outsourcing the development and manufacturing to a CDMO experienced in handling a range of products, in a multi-use facility, has proven to be an effective strategy.
access the Case Study!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.
Subscribe to Outsourced Pharma
X
Subscribe to Outsourced Pharma
Pharmaceutics International
This website uses cookies to ensure you get the best experience on our website. Learn more